Cullinan Therapeutics News - CGEM

Company Name	Stock Ticker Symbol	Market	Type
Cullinan Therapeutics Inc	CGEM	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.77	2.79%	28.35	20:00:00

Open Price	Low Price	High Price	Close Price	Prev Close
27.88	27.88	29.25	28.35	27.58

more quote information »

Recent News

Date	Time	Source	Heading
4/29/2024	07:00	GLOBE	Cullinan Therapeutics Announces Appointment of Mary Kay..
4/24/2024	10:09	GLOBE	Cullinan Therapeutics to Present Clinical Data from Phase 1..
4/16/2024	07:00	GLOBE	Cullinan Therapeutics Announces Strategic Expansion into..
4/16/2024	06:59	GLOBE	Cullinan Therapeutics Announces Oversubscribed $280 million..
3/14/2024	07:00	GLOBE	Cullinan Oncology Provides Corporate Update and Reports..
3/01/2024	07:00	GLOBE	Cullinan Oncology Announces U.S. FDA Clearance of..
2/27/2024	08:00	GLOBE	Cullinan Oncology to Participate in Upcoming Investor..
2/23/2024	17:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/23/2024	17:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/23/2024	17:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/14/2024	21:01	EDGAR2	Form SC 13G - Statement of acquisition of beneficial..
2/02/2024	21:35	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
2/01/2024	16:43	EDGAR2	Form 144 - Report of proposed sale of securities
1/30/2024	19:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/29/2024	16:27	EDGAR2	Form 144 - Report of proposed sale of securities
1/24/2024	17:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/22/2024	16:18	EDGAR2	Form 144 - Report of proposed sale of securities
1/08/2024	16:15	EDGAR2	Form 8-K/A - Current report: [Amend]
1/08/2024	09:12	EDGAR2	Form 8-K - Current report
12/22/2023	17:30	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/22/2023	17:30	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/22/2023	17:30	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/22/2023	17:30	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/20/2023	18:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/20/2023	18:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/20/2023	18:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/20/2023	18:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/18/2023	16:53	GLOBE	Cullinan Oncology to Present at the 42nd Annual J.P. Morgan..
12/14/2023	16:30	GLOBE	Cullinan Oncology Announces First Patient Dosed in Phase 1..
12/13/2023	20:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/13/2023	20:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/08/2023	07:22	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/08/2023	07:10	EDGAR2	Form 8-K - Current report
11/08/2023	07:00	GLOBE	Cullinan Oncology Provides Corporate Update and Reports..
11/03/2023	12:01	GLOBE	Cullinan Oncology to Present Data Demonstrating Progress..
10/30/2023	08:00	GLOBE	Cullinan Oncology to Participate in Upcoming Investor..
9/06/2023	08:00	GLOBE	Cullinan Oncology to Participate in Upcoming Investor..
8/10/2023	07:44	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/10/2023	07:07	EDGAR2	Form 8-K - Current report
8/10/2023	07:00	GLOBE	Cullinan Oncology Provides Corporate Update and Reports..
8/09/2023	07:00	GLOBE	Cullinan Oncology Announces First Patient Dosed in Phase 1..
8/03/2023	16:15	PRNUS	REZILIENT3 Global First-Line Trial of Zipalertinib Launched..
7/31/2023	08:00	GLOBE	Cullinan Oncology to Participate in Upcoming Investor..
7/05/2023	21:27	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
5/25/2023	17:00	GLOBE	Cullinan Oncology to Present First Monotherapy Clinical Data..
5/11/2023	16:01	GLOBE	Cullinan Oncology Provides Corporate Update and Reports..